Matthew is co-founder of Isomerase and has been its CEO since its formation. He is an experienced drug discovery professional skilled in programme management and intellectual property rights protection. He has extensive experience of drug discovery development and was previously Director of Intellectual Property and Project Management at Biotica Technology Ltd. At Biotica, he managed the intellectual property and collaborative research on internal projects from 2005-2013, with particular therapeutic focus in infectious diseases, inflammation and oncology. In doing so, he was also responsible for segregating internal programmes from collaborative research. Matthew joined Biotica in 2003, having been involved with the company since 1999 when he was at the University of Cambridge working on production of novel rapamycin analogues and genetic manipulation of the biosynthetic pathway in Professor Peter Leadlay’s group. Matthew has over 20 years of experience in actinomycete genetics, is an author or inventor on over 40 patents, patent applications or publications and holds a BSc in Biochemistry and Genetics and a PhD in Molecular Genetics from the University of Nottingham.